It was previously thought that variations in CYP3A4 and CYP3A5 were either too rare or too weak to seriously affect drug metabolism, however new research and discoveries have revealed strong evidence that certain variations are powerful predictors of drug metabolism.

CYP3A4 and CYP3A5 are members of the same enzyme family as CYP2D6, CYP2C9 and CYP2C19. Because of their clinical utility, Genelex is expanding its testing repertoire and standard YouScript panel to include these two new genes.

Over 350 CYP3A4 and CYP3A5-dependent drugs are recognized in YouScript, including important cardiac and pain medication such as simvastatin, lovastatin, oxycodone and fentanyl.

Adding these genes will greatly improve YouScript’s precision and predictive ability. Prescribers should go to www.youscript.com to learn more about CYP3A4 and CYP3A5!